Oppenheimer analyst Trevor Allred upgraded BridgeBio (BBIO) to Outperform from Perform with a $60 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma Enters Royalty Purchase Agreement
- Strategic Financial Maneuvers and Growth Potential: BridgeBio Pharma’s Path to Profitability
- BridgeBio raises $300M via parital capped monetization of European royalty
- 3 Best Stocks to Buy Now, 6/30/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 6/26/2025, According to Top Analysts